Today: 1 July 2026
Visa stock ticks up before the bell after earnings beat as cross-border trends come into focus
30 January 2026
1 min read

Visa stock ticks up before the bell after earnings beat as cross-border trends come into focus

NEW YORK, Jan 30, 2026, 05:06 EST — Premarket

  • Visa shares inched up early on after the card network beat quarterly estimates.
  • After a hectic holiday quarter, investors are digging into cross-border moves and the cost outlook.
  • Friday’s American Express earnings report may steer the mood on payment stocks.

Visa shares climbed roughly 1.4% to $331.80 in U.S. premarket trading Friday, following the release of the company’s latest quarterly results.

Visa reported adjusted net income of $6.1 billion, or $3.17 per share, for the quarter ending Dec. 31. Revenue jumped 15% to $10.90 billion, surpassing analyst estimates compiled by LSEG. On a constant-dollar basis, global payment volumes climbed 8%, excluding currency effects. Cross-border volume — a higher-margin segment linked to travel and overseas spending — grew 12%, though the pace slowed compared to last year. Shares dipped about 1% in extended trading after the announcement. Finance chief Chris Suh said tariffs hadn’t caused “a meaningful impact.” Visa also highlighted progress integrating stablecoins, including a pilot allowing some U.S. banks to settle with Visa using Circle’s USDC token. Reuters

The report is crucial now since card networks offer one of the clearest, quickest glimpses into consumer spending amid a noisy macro environment. Just a few percentage points’ change in spending or travel can swiftly impact fee growth, prompting investors to move ahead of broader data releases.

Cross-border payments often grab traders’ attention first. Driven by shifts in travel, trade flows, and currency movements, they usually reflect deeper economic trends than domestic swipe volume.

Visa projects low-double-digit revenue growth for both its second quarter and full fiscal year, with earnings per share growth expected toward the upper end of that range. The company repurchased 11 million shares, spending $3.8 billion, and set aside $500 million in a litigation escrow account.

Visa entered the quarter on weaker footing. The stock dropped 1.9% during Thursday’s regular session and has slid 5.4% so far this year. Investors remain wary amid Washington’s scrutiny of card fees and credit rates, with fresh debates over swipe fees heating up. Meanwhile, Visa’s board announced a quarterly cash dividend of $0.67 per share.

Investors might stop valuing steady volume growth and begin pricing in potential setbacks: a bigger rise in operating costs, increased fee pressure, or a sharper drop in travel-driven spending. Tariffs pushing prices up often hit lower-income consumers first, with payment data typically revealing that shift early on.

In premarket moves, Mastercard gained roughly 4.2%, while American Express edged up around 0.3%.

Visa disclosed in a separate filing this week that shareholders have approved changes to its certificate of incorporation, aimed at limiting certain officer liabilities under Delaware law.

Visa plans to release its upcoming quarterly earnings on April 28, Investing.com reports.

Before the opening bell on Friday, American Express will release its fourth-quarter results at 8:30 a.m. ET.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Galderma Shares Drop on FDA Denial of Relfydess Botox Rival
    July 1, 2026, 4:28 AM EDT. Galderma Group AG shares dropped sharply, posting their steepest fall in more than a year after the FDA turned down its Botox competitor Relfydess. Investors sold on news of the decision, worrying about Galderma's push into the Botox segment. The move is a setback for the Swiss company's plans to grow in the cosmetic treatment market.
Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target
Previous Story

Intuit stock price dips as AI fears circle TurboTax, but RBC sticks with $850 target

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers
Next Story

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers

Go toTop